07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Macrophage stimulating protein (MSP; MST1); serine/threonine kinase 3 (STK3; MST2)

Gastrointestinal disease INDICATION: Colitis; hepatic; liver fibrosis Mouse studies suggest combined inhibition of MSP and STK3 could help treat colitis, liver damage and liver fibrosis. In a mouse model of chemical-induced colitis, a dual MSP/STK3 inhibitor tool...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Illumina, Oxford Nanopore genomics news

Illumina filed two concurrent lawsuits against Oxford Nanopore alleging that the nanopore-based sequencing company’s MinION and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina alleged that MinION and PromethION infringe on U.S....
01:07 , Feb 25, 2016 |  BC Extra  |  Company News

Illumina suing Oxford Nanopore

Illumina Inc. (NASDAQ:ILMN) filed two concurrent lawsuits against nanopore-based sequencing company Oxford Nanopore Technologies Ltd. (Oxford, U.K.) alleging that Oxford Nanopore's MinION and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina is...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Manchester Science Parks (MSP) pharmaceuticals news

AstraZeneca will sell its facility in Alderley Park, U.K., to MSP, a public-private science park operator. The pharma expects to complete the sale of the facility - which was focused on small molecule R&D -...
07:00 , May 30, 2013 |  BC Innovations  |  Cover Story

RON's new role

A Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response.1 The findings build a case for directed drug discovery efforts against the target, which has...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

MDxHealth, Takara Bio deal

Takara received a non-exclusive, worldwide license to use MDxHealth's methylation specific PCR ( MSP) technology as part of its research tools which are used to identify methylation patterns in cancer. MDxHealth will receive an upfront...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Serine/threonine kinase 4 (STK4; MST1); Serine/threonine kinase 3 (STK3) (MST2); SAV1 salvador family WW domain containing...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Clinical News

Stool-based colorectal cancer assay diagnostic data

A preliminary analysis of stools from the first 147 patients enrolled in a biomarker study showed that 2 ONCO methylation genes detected early stage colorectal cancer with 86% sensitivity and 96% specificity. The trial is...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

Exact Sciences, OncoMethylome deal

ONCO received a non-exclusive license to EXAS's DNA stabilization, isolation and extraction technology to develop and market stool-based diagnostics to detect colorectal cancer. EXAS is eligible for royalties. Separately, ONCO will supply reagents to EXAS...
07:00 , Jun 12, 2006 |  BioCentury  |  Finance

Tysabri chronicles

Tysabri chronicles Biogen Idec's stock moves have been less volatile than those of Elan following good or bad news related to their Tysabri MS drug. The reason is BIIB is more insulated - the company is...